Net Income (Loss) Attributable to Parent in USD of Cullinan Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cullinan Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2020 to Q3 2025.
  • Cullinan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$50,610,000.000, a 24.8% decline year-over-year.
  • Cullinan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$216,813,000.000, a 51% decline year-over-year.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$167,383,000.000, a 9.29% decline from 2023.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$153,162,000.000, a 238% decline from 2022.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $111,214,000.000.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Cullinan Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$216,813,000 -$50,610,000 -$10,050,000 -24.8% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$206,763,000 -$70,055,000 -$28,027,000 -66.7% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$178,736,000 -$48,501,000 -$11,353,000 -30.6% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 -$167,383,000 -$47,647,000 -$23,844,000 -1% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025
Q3 2024 -$143,539,000 -$40,560,000 -$1,377,000 -3.5% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$142,162,000 -$42,028,000 -$9,814,000 -30.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$132,348,000 -$37,148,000 +$20,814,000 +35.9% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 -$153,162,000 -$23,803,000 +$2,979,000 +11.1% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025
Q3 2023 -$156,141,000 -$39,183,000 -$14,379,000 -58% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$141,762,000 -$32,214,000 -$207,112,000 -1.2% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $65,350,000 -$57,962,000 -$45,864,000 -3.8% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 $111,214,000 -$26,782,000 +$5,732,000 +17.6% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024
Q3 2022 $105,482,000 -$24,804,000 -$7,454,000 -43% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $112,936,000 $174,898,000 +$190,534,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$77,598,000 -$12,098,000 -$12,028,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$65,570,000 -$32,514,000 -$4,168,000 -14.7% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023
Q3 2021 -$61,402,000 -$17,350,000 -$7,492,000 -76% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$53,910,000 -$15,636,000 -$7,014,000 -81.4% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 -$46,896,000 -$70,000* +$4,903,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$51,799,000 -$28,346,000 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022
Q3 2020 -$9,858,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$8,622,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021
Q1 2020 -$4,973,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021

Cullinan Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$167,383,000 -$14,221,000 -9.3% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025
2023 -$153,162,000 -$264,376,000 -2.4% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025
2022 $111,214,000 +$176,784,000 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024
2021 -$65,570,000 -$13,771,000 -26.6% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023
2020 -$51,799,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.